Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Vigil Neuroscience Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VIGL
Nasdaq
8731
https://www.vigilneuro.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Vigil Neuroscience Inc
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 26th, 2024 11:05 am
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
- Mar 24th, 2024 1:15 pm
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
- Mar 20th, 2024 11:05 am
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
- Mar 13th, 2024 11:05 am
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
- Mar 12th, 2024 11:05 am
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
- Mar 6th, 2024 9:25 pm
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
- Feb 29th, 2024 9:05 pm
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
- Feb 7th, 2024 9:05 pm
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
- Jan 3rd, 2024 9:30 pm
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
- Nov 22nd, 2023 9:05 pm
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
- Nov 16th, 2023 9:05 pm
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 7th, 2023 12:05 pm
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
- Oct 17th, 2023 11:05 am
Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely?
- Oct 15th, 2023 2:23 pm
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
- Oct 5th, 2023 8:01 pm
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
- Sep 26th, 2023 11:05 am
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
- Sep 11th, 2023 4:00 pm
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
- Sep 8th, 2023 8:05 pm
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
- Sep 8th, 2023 11:05 am
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 8th, 2023 11:05 am
Scroll